Diabetic retinopathy
Diabetic retinopathy (DR) is the most important manifestation of diabetic microangiopathy. It is a fundus lesion with specific changes and one of the serious complications of diabetes. Clinically, based on the presence or absence of retinal neovascularization, diabetic retinopathy without retinal neovascularization is called nonproliferative diabetic retinopathy (NPDR) (or simple type or background type), while diabetic retinopathy with retinal neovascularization is called proliferative diabetic retinopathy (PDR). Diabetes can cause two types of retinopathy - proliferative and nonproliferative retinopathy. Diabetic retinopathy is one of the main causes of blindness. Diabetic retinopathy can occur regardless of whether insulin is used for treatment. Diabetic damage to the retina is mainly due to increased blood sugar, thickening of the walls of small blood vessels, increased permeability, and making small blood vessels more prone to deformation and leakage. The severity of diabetic retinopathy and the degree of vision loss are related to the control of blood sugar levels and the length of time of diabetes. The duration of illness is particularly important. Diabetic retinopathy usually occurs at least 10 years after the onset of diabetes.
-
Site of disease:
Pancreatic eye -
Infectious :
Not contagious -
Frequent population:
Diabetic patients -
Related symptoms:
Retinal hemorrhage polyuria retinal edema distorted vision fundus changes -
Concurrent disease:
Related Drugs
Xylitol Injection
Indication: It is used to supplement energy and body fluids, adjust metabolism, relieve symptoms, and eliminate ketonemia in diabetic patients. It can also be used for sugar supplementation during surgical anesthesia for various sugar metabolism disorders.
Manufacturer:
Cisen Pharmaceutical Co., Ltd.
AHZANTIVE- aflibercept-mrbb_injection, solution
Indication: 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1. 1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) AHZANTIVE is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) (1. 1) Macular Edema Following Retinal Vein Occlusion (RVO) (1. 2) Diabetic Macular Edema (DME) (1. 3) Diabetic Retinopathy (DR) (1.
Manufacturer:
Valorum Biologics Inc
SUSVIMO- ranibizumab_injection, solution
Indication: SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1. 1 Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1. 2 Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1. 3 SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication. SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication. SUSVIMO (ranibizumab injection) is indicated for the treatment of patients with Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor medication.
Manufacturer:
Genentech, Inc.
Related Ingredients